Roche commits over $1 billion to DualityBio for ADC development targeting TOP1 resistance

Roche's Genentech unit announced a major investment in DualityBio to advance antibody-drug conjugate (ADC) technology.

Under the agreement DualityBio will receive an upfront payment of $45 million, part of a broader commitment that Roche expects to exceed $1 billion.

The collaboration will focus on creating ADCs designed to overcome resistance to topoisomerase I (TOP1) targeting agents, a key challenge in oncology.

If successful, the partnership could add new candidates to Roche's pipeline and support the emerging wave of next-generation ADC therapeutics.